Highlights BioNxt Solutions Inc.

Equities

BNXT

CA0909741062

Market Closed - Canadian Securities Exchange Other stock markets 20:22:49 25/06/2024 BST			5-day change	1st Jan Change
0.3 ^CAD	-6.25%		0.00%	-38.14%

05-29	BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	BioNxt Solutions Inc. Announces ODF Cladribine Update	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
BioNxt Solutions Inc. Announces ODF Cladribine Update	04-26	CI
BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps	03-18	CI
BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study	03-13	CI
BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study	02-07	CI
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing	12-22	CI
BioNxt Solutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program	11-15	CI
BioNxt Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	27/08/23	CI
BioNxt Solutions Inc. Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease	02/08/23	CI
BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease	15/05/23	CI
BioNxt Completes Pilot Study for Contract Development Customer	09/05/23	MT
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Co	24/04/23	MT
BioNxt Acquires Equipment For European Commercial Manufacturing Capacity, Updates Enteric Coating Drug Delivery Program	17/04/23	MT
BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	12/04/23	CI
BioNxt Solutions Acquired Novel Precision Drug Coating and Delivery Technology	07/03/23	MT
BioNxt Solutions Inc. Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson's Disease	02/03/23	CI
BioNxt Solutions Inc. Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease	13/02/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioNxt Solutions Inc.

Equities

BNXT

CA0909741062

Highlights

Filters